Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$1,036.52 USD
+9.97 (0.97%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $1,043.70 +7.18 (0.69%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Regeneron Pharmaceuticals, Inc. [REGN]
Reports for Purchase
Showing records 341 - 360 ( 592 total )
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We are dropping coverage due to the departure of the covering analyst.
Provider: Roth Capital Partners, Inc.
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q16 Results; Revenue Pushes Forward; Pipeline Progress Continues
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
8-K Points to Sarilumab CRL or Delay At Minimum; Investment Case Intact
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
No Surprise Here; Sarilumab CRL, But Think Easy to Overcome
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
A Time-Out to Adjust the Fasinumab Game Plan
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Full Dupixent Data Shine; Bring on the PDUFA Date
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J